Healthy Skepticism Library item: 15467
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: news
IMS World Pharmaceutical Market Summary April 2009
IMS Health 2009 Apr 23
http://view.respond.imshealth.com/?j=fe9313767466007876&m=fef31377726304&ls=fdf51577706d027d77137070&l=fe9c15707462047873&s=fe29157773640379751c75&ju=fe4d13737c630c7e701c&r=0
Full text:
Sales Through Retail Pharmacies (Twelve months to February 2009*)
NORTH AMERICA $222.9 billion up 2%
U.S.A. $206.7 billion up 2%
CANADA $16.1 billion up 6%
EUROPE (TOP 5) $111.3 billion up 1%
GERMANY $34.4 billion up 2%
FRANCE $30.0 billion up 0%
UK $15.0 billion down 2%
ITALY $16.7 billion up 0%
SPAIN $15.0 billion up 3%
JAPAN (including hospitals) $70.8 billion up 2%
LATIN AMERICA (TOP 3) $23.5 billion up 9%
BRAZIL $12.0 billion up 11%
MEXICO $8.1 billion up 0%
ARGENTINA $3.2 billion up 22%
VENEZUELA $4.5 billion up 31%
AUSTRALIA/NZ $7.5 billion up 7%
The top 5 therapy classes at ATC3 level in the 12 months to February 2009 were:
1. C10A – Cholesterol & trigly. regulators
2. A2B – Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A – Antipsychotics
5. N3A – Anti-epileptics
The top 5 products in the 12 months to February 2009 were:
1. Lipitor
2. Plavix
3. Nexium
4. Seretide/Advair
5. Enbrel
The top 5 corporations in the 12 months to February 2009 were:
1. Pfizer
2. GlaxoSmithKline
3. AstraZeneca
4. Novartis
5. Sanofi-Aventis
